Income Statement
Revenue$1.2B
Gross Profit$750.3M
Operating Income$255.3M
EBITDA$339.7M
Net Income$199.5M
DXCM
DexCom, Inc.
NMSSector: HealthcareIndustry: Medical Devices
Valuation
Market Cap
$26.77B
Enterprise Value
$25.88B
P/E
29.8
TTMFwd P/E
22.5
1YP/B
9.1
P/S
5.6
TTMPEG
1.30
EV/EBITDA
20.0
EV/Revenue
5.4
FCF Yield
3.4%
EPS (TTM)
$2.33
Fwd EPS
$3.08
Book Value
$7.66
Market Data
Beta
1.44
Avg Volume
5.5M
Shares Out
385.9M
Float
384.5M
Short % Float
5.2%
Insider %
0.3%
Institutional %
102.5%
D/E
46.8
Current Ratio
1.9
ROE
35.6%
ROA
9.7%
Rev Growth
15.0%
Net Inc Growth
92.2%
Profit Margin
19.3%
Op Margin
21.4%
Gross Margin
61.5%
Total Cash
$2.42B
Total Debt
$1.38B
Financials
Latest period financial summary
Balance Sheet
Total Assets$6.6B
Current Assets$4.3B
Cash$1.1B
Total Liabilities$3.7B
Equity$3.0B
Total Debt$1.4B
Cash Flow
Operating CF$525.6M
Investing CF$-298.5M
Financing CF$-25.0M
Free Cash Flow$449.0M
Financial Trends
Revenue$1.2B
2022/122026/3
Net Income$199.5M
2022/122026/3
EBITDA$339.7M
2022/122026/3
Free Cash Flow$449.0M
2022/122026/3
Period Analysis
Margins & Ratios
| Metric | 2021/12 | 2022/12 | 2023/12 | 2024/9 | 2024/12 | 2025/3 | 2025/6 | 2025/9 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.9B | $3.6B | — | $4.0B | $1.0B | $1.2B | $1.2B |
| Gross Margin | — | +64.7% | +63.2% | — | +60.5% | +56.9% | +59.5% | +60.5% |
| EBITDA Margin | — | +19.4% | +25.3% | — | +23.4% | +21.1% | +26.7% | +34.8% |
| Operating Margin | — | +13.4% | +16.5% | — | +14.9% | +12.9% | +18.4% | +20.1% |
| Net Margin | — | +11.7% | +14.9% | — | +14.3% | +10.2% | +15.5% | +23.5% |
| Current Ratio | — | 1.99 | 2.84 | — | 1.47 | 1.50 | 1.52 | 1.56 |
| Debt / Equity | — | 1.01 | 1.25 | — | 1.23 | 1.14 | 1.00 | 0.94 |
| Net Debt / EBITDA | — | 2.66 | 2.21 | — | 2.10 | 7.66 | 4.60 | 1.76 |
| ROE | — | +16.0% | +26.2% | — | +27.4% | +4.7% | +7.0% | +10.4% |
| ROA | — | +6.3% | +8.6% | — | +8.9% | +1.6% | +2.5% | +3.8% |
| Leverage | — | 0.60 | 0.67 | — | 0.68 | 0.66 | 0.65 | 0.64 |
Company Profile
DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Employees
11K
Location
San Diego, CA
Country
US
Golden Bazaar VerifiedUpdated: Jun 25, 2026Data Source: Golden Bazaar Verified · Updated: Jun 25, 2026
Sector Peers
Comparison Screen →Healthcare
Compare with similar companies in the same sector.
This page is prepared by Golden Bazaar using publicly available data. Not investment advice.